Pharmicell announced on the 10th that it recorded sales of 64.9 billion KRW, operating profit of 4.8 billion KRW, and net profit of 6.5 billion KRW last year. Compared to the previous year, sales increased by 15%, operating profit by 267%, and net profit by 82%.
Sales of Pharmicell's Biochemical Division, which produces active pharmaceutical ingredients and low dielectric constant materials, amounted to 62.8 billion KRW, a 12% increase from the previous year. The Biomedical Division, which produces stem cell therapeutics, recorded sales of 2.1 billion KRW, up 25%. The Biochemical Division accounts for 97% of total sales.
The advanced AI material, low dielectric constant material, which has grown into a core business area, led the performance growth. Sales of low dielectric constant materials reached 29.8 billion KRW, growing 227% year-on-year. It also accounts for 46% of total sales.
A Pharmicell representative explained, "Sales of low dielectric constant materials in the fourth quarter alone increased significantly to 14.4 billion KRW," adding, "We were able to record the highest quarterly sales and all-time highest sales." They continued, "We are producing to supply low dielectric constant materials using all facilities of Ulsan Plant 1 and Plant 2," and said, "Pharmicell's growth trend will continue this year as well."
Low dielectric constant materials are key components of copper clad laminates (CCL) and are used in AI accelerators. Demand is rapidly increasing due to the AI boom led by Nvidia.
The Biomedical Division completed patient recruitment for the Phase 2 clinical trial of the erectile dysfunction stem cell therapeutic in December last year. With the enforcement of the amended Advanced Regenerative Bio Act allowing treatment after advanced regenerative medical clinical research, Pharmicell plans to actively advance its CDMO business related to stem cell therapeutics to establish a foundation for growth.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
